By the Corex Vitality™ Research Team · Last checked 7 November 2026 · Sources listed under Published Research
Quick summary
- Survodutide (code name BI 456906) is an investigational peptide that activates two receptors: the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R).
- Its design follows oxyntomodulin, a natural gut peptide that also acts on both receptors.
- It carries a C18 fatty acid, which its developer describes as the part that extends its half-life.
- This guide covers the published chemistry and laboratory pharmacology. It is not an approved medicine, and this guide does not discuss personal use.
Survodutide is one of several “dual agonist” peptides in development. This plain-English guide to survodutide research sets out what the published papers cover: where the idea came from, how the molecule is built, and how its developer measured its activity in cells and in animal models. For the wider family of receptor peptides, see our GLP-1, GIP and glucagon receptor guide.
1. First, some basic words
- A receptor is a protein on the surface of a cell. When the right molecule binds, the cell sends a signal inside.
- An agonist is a molecule that switches a receptor on. A dual agonist switches on two different receptors.
- GLP-1R and GCGR are closely related receptors. Both are G-protein-coupled receptors that raise a messenger molecule called cAMP inside the cell.
- Potency describes how little of a molecule is needed to give half of its maximum effect in an assay (the EC50).
- Preclinical means work done in cells, tissues or animals before any study in people.
2. Where the idea came from: oxyntomodulin
Oxyntomodulin is a 37-amino-acid peptide made in the gut. It activates both GLP-1R and GCGR, which is why researchers studied it as a template for dual agonists. Natural oxyntomodulin is broken down quickly, mainly by the enzyme DPP-IV, which cuts two amino acids from the front of the chain.
An early structure-activity study changed the oxyntomodulin sequence step by step. It found changes that blocked DPP-IV cutting and raised potency, showed that attaching a lipid group lengthened the peptide’s action in animal studies, and found that a single amino-acid swap could turn the dual agonist into a GLP-1R-only agonist. That last finding is important: small changes in sequence can shift the balance between the two receptors.
3. How survodutide is built
The discovery paper describes survodutide as a potent acylated peptide carrying a C18 fatty acid. The developer describes this chain as its half-life-extending part. As with other lipidated peptides, a fatty-acid chain of this kind is designed to bind loosely to albumin, the main carrier protein in blood plasma. If you want the background chemistry, our article on retatrutide structure and its fatty-acid chain explains how this works on a related molecule.
4. How it was picked from 19 candidates
A 2024 paper from the developer explains how survodutide was chosen from a panel of 19 dual GCGR/GLP-1R agonists. The team used several layers of testing:
- Cell assays with human receptors: cAMP potency was measured in CHO-K1 cells engineered to carry human GCGR or human GLP-1R.
- Cells with natural receptors: a mouse pancreatic cell line (MIN6) was used for the mouse GLP-1R, and rat primary liver cells (hepatocytes) for the glucagon receptor.
- Target-engagement markers in mice: for the glucagon receptor they measured liver NNMT mRNA and blood FGF21. These markers rise when the liver’s glucagon receptors are switched on.
Across the 19 molecules, the animal markers lined up with the cell potencies. Three candidates went forward for deeper profiling, and survodutide was chosen for its balance between the two receptors.
The earlier discovery paper also used GLP-1R knockout mice (mice without the receptor), reporter mice and an ex-vivo bioactivity assay to confirm that both receptors were being engaged.
5. Why receptor balance is hard to get right
The ratio of GLP-1R to GCGR activity is the main design choice for this kind of peptide. A study of a different long-acting co-agonist, NN1177, tested it alongside two related molecules with different receptor ratios. The results at a given ratio differed between mice and rats, and also depended on how much compound was present and how long the study ran. The authors concluded that these species differences make the optimally balanced molecule hard to predict from animal work alone.
This is a useful reminder when reading any preclinical paper: a result in one species, at one time point, is a starting point, not a final answer.
6. What the research does not cover here
Survodutide is still in development and is not an approved medicine in the UK or elsewhere. Its developer is running studies in people, but those are outside the scope of this guide, which covers only the chemistry and laboratory pharmacology. Nothing here should be read as information about personal use.
7. What labs measure for dual agonists
- Receptor potency: cAMP assays in cells carrying each receptor give an EC50 for GLP-1R and for GCGR. Comparing the two gives the receptor balance.
- Selectivity: the same assays run with related receptors (for example the GIP receptor) show whether the peptide stays on target. Our guide to multi-agonist signalling covers this.
- Purity: reversed-phase HPLC separates the main peptide from related substances. See reading an HPLC chromatogram and peptide impurities explained.
Key takeaways
- Survodutide (BI 456906) is an investigational dual agonist of the glucagon receptor and the GLP-1 receptor.
- Its design builds on oxyntomodulin, a natural dual-acting gut peptide, and it carries a C18 fatty acid to extend its half-life.
- It was chosen from 19 candidates using cAMP assays, native-receptor cell assays and liver markers (NNMT, FGF21) in mice.
- Receptor balance behaves differently between species, so preclinical results need careful reading.
- For related in-vitro research, see the Retatrutide research vials, the batch verification page and the Learning Hub.
Published Research
The peer-reviewed papers below were used for the science in this article. Each entry was checked against PubMed on 7 November 2026. Summaries describe chemistry, laboratory and cell-based findings only. Corex Vitality™ is not affiliated with the cited authors, journals or institutions.
- BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-metabolic dysregulation efficacy. Zimmermann T, Thomas L, Baader-Pagler T, et al. Mol Metab. 2022;66:101633. PMID: 36356832 · DOI: 10.1016/j.molmet.2022.101633
Discovery paper from the developer. Describes BI 456906 (survodutide) as an acylated peptide carrying a C18 fatty acid, profiled in cell-based receptor assays and in mouse studies, including GLP-1 receptor knockout and reporter mice and an ex-vivo bioactivity assay to confirm activity at both receptors. - The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection. Thomas L, Martel E, Rist W, et al. glycaemic signalling Obes Metab. 2024;26(6):2368-2378. PMID: 38560764 · DOI: 10.1111/dom.15551
Explains how 19 dual GCGR/GLP-1R agonists were compared: cAMP potency in CHO-K1 cells expressing the human receptors, endogenous receptors in MIN6 cells and rat primary hepatocytes, and liver NNMT mRNA and plasma FGF21 as markers of glucagon-receptor engagement in mice. Survodutide was chosen from this panel. - Unraveling oxyntomodulin, GLP1's enigmatic brother. Pocai A. J Endocrinol. 2012;215(3):335-46. PMID: 23019069 · DOI: 10.1530/JOE-12-0368
Review of oxyntomodulin, a natural gut peptide that activates both the GLP-1 receptor and the glucagon receptor, and the reasoning behind designing dual agonists based on it. - DPP-IV-resistant, long-acting oxyntomodulin derivatives. Santoprete A, Capitò E, Carrington PE, et al. J Pept Sci. 2011;17(4):270-80. PMID: 21294225 · DOI: 10.1002/psc.1328
Structure-activity study of oxyntomodulin analogues. Reports changes that made the peptide resistant to the enzyme DPP-IV, a lipid (cholesterol) attachment that lengthened its action in vivo, and a single substitution that switched the profile from dual to GLP-1-receptor-selective. - Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. Simonsen L, Lau J, Kruse T, et al. PLoS One. 2022;17(3):e0264974. PMID: 35245328 · DOI: 10.1371/journal.pone.0264974
Preclinical study of another long-acting GLP-1/glucagon co-agonist (NN1177) alongside two analogues with different receptor ratios. Found that results at a given receptor ratio differed between mice and rats and depended on exposure and study length, which makes the ideal balance hard to predict.
All Corex Vitality™ products are supplied strictly for in-vitro laboratory research use only. Not for human or veterinary use. No information here describes use in humans or animals.

Free guide
How to read a COA
Get it by email, plus our research updates. No spam, unsubscribe any time.